See more : Aigan Co.,Ltd. (9854.T) Income Statement Analysis – Financial Results
Complete financial analysis of DV Biomed Co., Ltd. (6539.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DV Biomed Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Sovereign Cloud Holdings Limited (SOV.AX) Income Statement Analysis – Financial Results
- LEG Immobilien SE (LEG.SG) Income Statement Analysis – Financial Results
- Shuz Tung Machinery Industrial Co., Ltd. (4537.TWO) Income Statement Analysis – Financial Results
- Slate Office REIT (SLTTF) Income Statement Analysis – Financial Results
- Catapult Group International Limited (CAZGF) Income Statement Analysis – Financial Results
DV Biomed Co., Ltd. (6539.TWO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.dvbiomed.com
About DV Biomed Co., Ltd.
DV Biomed Co., Ltd. manufactures and sells medical-grade skin care products in Taiwan and internationally. The company provides health and slimming services; and acts as an agent of medical beauty fillers and medical beauty equipment. It also offers health food, including light and energy drinks; face care; and beauty products and services. The company was founded in 2011 and is based in Taipei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 1.54B | 1.87B | 1.83B | 1.81B | 1.93B |
| Cost of Revenue | 774.08M | 827.29M | 804.96M | 886.25M | 953.26M |
| Gross Profit | 764.28M | 1.04B | 1.02B | 925.51M | 977.19M |
| Gross Profit Ratio | 49.68% | 55.67% | 55.95% | 51.08% | 50.62% |
| Research & Development | 12.33M | 12.84M | 12.44M | 31.95M | 104.98M |
| General & Administrative | 141.05M | 128.41M | 114.52M | 123.42M | 143.38M |
| Selling & Marketing | 436.33M | 511.31M | 478.40M | 500.56M | 570.51M |
| SG&A | 577.37M | 639.72M | 592.92M | 623.98M | 709.11M |
| Other Expenses | 0.00 | 7.28M | 9.00M | 97.94M | 0.00 |
| Operating Expenses | 575.24M | 652.56M | 605.36M | 655.93M | 822.04M |
| Cost & Expenses | 1.36B | 1.48B | 1.41B | 1.54B | 1.78B |
| Interest Income | 6.43M | 2.22M | 537.00K | 390.00K | 735.00K |
| Interest Expense | 7.04M | 5.21M | 4.45M | 4.78M | 6.82M |
| Depreciation & Amortization | 194.03M | 183.58M | 182.66M | 179.41M | 84.76M |
| EBITDA | 407.64M | 582.63M | 610.85M | 545.48M | 247.87M |
| EBITDA Ratio | 26.50% | 29.65% | 31.80% | 28.84% | 12.84% |
| Operating Income | 173.55M | 369.67M | 398.43M | 343.17M | 163.11M |
| Operating Income Ratio | 11.28% | 19.81% | 21.81% | 18.94% | 8.45% |
| Total Other Income/Expenses | 14.87M | -21.86M | -22.89M | 68.82M | -14.04M |
| Income Before Tax | 188.42M | 365.06M | 395.76M | 336.55M | 149.07M |
| Income Before Tax Ratio | 12.25% | 19.56% | 21.66% | 18.58% | 7.72% |
| Income Tax Expense | 35.40M | 76.06M | 91.19M | 51.87M | 49.74M |
| Net Income | 162.91M | 281.26M | 304.58M | 301.40M | 166.28M |
| Net Income Ratio | 10.59% | 15.07% | 16.67% | 16.64% | 8.61% |
| EPS | 2.72 | 13.59 | 14.60 | 14.34 | 7.84 |
| EPS Diluted | 2.72 | 13.56 | 14.57 | 14.31 | 7.83 |
| Weighted Avg Shares Out | 59.79M | 20.70M | 20.86M | 21.04M | 21.22M |
| Weighted Avg Shares Out (Dil) | 59.85M | 20.73M | 20.86M | 21.06M | 21.23M |
Source: https://incomestatements.info
Category: Stock Reports